

PRODUCT INFORMATION

| | |
|---|---|
| Common Name | RN624, PF-04383119 |
| Conjugate | Unconjugated |
| Synonyms | NGFB |
| Applications | N/A |
| Endotoxin | Less than 1.0 EU/ μ g by the LAL method. For <1 EU/mg requirements, please contact us for customization. |
| Recommended Dilutions | N/A |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | Humanized |
| IgG type | Human IgG2(A330S,P331S,S378A)-kappa |
| Reactivity | Human |
| Target | NGF |
| Uniprot ID | P01138 |
| Description | Anti-NGF(tanezumab biosimilar) mAb |
| Delivery | In Stock |
| Storage&Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature. |
| Sterility | Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μ m) prior to use. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |






Figure 1. Anti-NGF(tanezumab biosimilar) mAb on SDS-PAGE under reducing (R) and non-reducing (NR) conditions.

DIMABIO CONFIDENTIAL

